

EMMESSAR BIOTECH & NUTRITION LTD					
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2016					Rs. In lacs
Particulars	Current 3 months ended 31.03.2016	Preceeding 3 months ended	Corresponding Qtr ended 31.03.2015	Current Year ended 31.03.2016	Previous year ended 31.03.2015
	Audited (1)	Unaudited (2)	Audited (3)	Audited (4)	Audited (5)
<b>PART I</b>					
<b>01) Income from Operations</b>					
(a) Net Sales / Income from operations (Net of Excise Duty)	51.24	15.81	7.55	197.44	219.03
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00
<b>Total Income</b>	<b>51.24</b>	<b>15.81</b>	<b>7.55</b>	<b>197.44</b>	<b>219.03</b>
<b>02) Expenditure</b>					
(a) Cost of material consumed	0.96	1.34	18.92	53.56	102.27
(b) Purchase of Stock-trade	0.00	0.00	0.00	5.48	0.00
(c) Change in inventories of Finished goods	52.61	1.14	(36.24)	37.16	(26.95)
(d) Employee Benefit Expenses	8.55	7.28	8.40	31.10	28.42
(e) Depreciation & amortisation of Assets	1.62	0.37	1.73	2.72	6.87
(f) Other Expenditure	2.37	5.19	25.35	69.04	129.88
<b>(g) Expenditure (a to f)</b>	<b>66.11</b>	<b>15.32</b>	<b>18.16</b>	<b>199.06</b>	<b>240.49</b>
03) Profit / (loss) from Operations before Other Income, Interest & Exceptional items(1 - 2)	(14.87)	0.49	(10.61)	(1.62)	(21.46)
04) Other Income	16.08	1.22	0.37	25.87	5.73
05) Profit / (Loss) before Interest and Exceptional Items (3 + 4)	1.21	1.71	(10.24)	24.25	(15.73)
06) Interest	0.00	0.00	0.00	0.00	0.00
07) Profit / (Loss) after Interest but before Exceptional Items (5 - 6)	1.21	1.71	(10.24)	24.25	(15.73)
08) Exceptional Items	0.00	0.00	0.00	(92.17)	0.00
09) Profit / (Loss) from Ordinary Activities Before Taxation (7 + 8)	1.21	1.71	(10.24)	(67.92)	(15.73)
10) Tax Expense (Deferred Tax)	(21.39)	0.00	(3.94)	(21.39)	(3.94)
11) Net Profit / (Loss) from Ordinary Activities after Taxation (9 - 10)	22.60	1.71	(6.30)	(46.53)	(11.79)
12) Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00
13) Net Profit / (Loss) for the period (11-12)	22.60	1.71	(6.30)	(46.53)	(11.79)
14) Share of profit / loss of associates	NA	NA	NA	NA	NA
15) Minority Interest	NA	NA	NA	NA	NA
16) Net profit / (loss) for the period (13 + 14 + 15)	22.60	1.71	(6.30)	(46.53)	(11.79)
17) Paid-up Equity Share Capital (Face Value of the share)	499.61	499.61	499.61	499.61	499.61
18) Reserves excluding Revaluation Reserve as per Balance Sheet of previous accounting year	10.00	10.00	10.00	10.00	10.00
18) Reserves excluding Revaluation Reserve as per Balance Sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00
19) Earning per Shares	0.45	0.03	(0.13)	(0.93)	(0.24)
a) Basic & diluted EPS before Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)					
b) Basic & diluted EPS after Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)	0.45	0.03	(0.13)	(0.93)	(0.24)
<b>PART II</b>					
<b>A. PARTICULARS OF SHAREHOLDINGS</b>					
1) Public Shareholding					
- No. of Shares	2020385	2076069	2302713	2020385	2302713
- Percentage of Shareholding	40.44	41.55	46.09	40.44	46.09
2) Promoters & Promoter Group Shareholding					
a) Pledged / Encumbered					
- No. of Shares	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as % of the total Share Capital of the Company)					
b) Non Encumbered					
- No. of Shares	2975715	2920031	2693387	2975715	2693387
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00
- Percentage of shares (as % of the total Share Capital of the Company)	59.56	58.45	53.91	59.56	53.91
Particulars <b>Three Months ended 31.03.2016</b>					
<b>B. INVESTORS COMPLAINTS</b>					
Pending at the beginning of the quarter	NIL				
Received during the quarter	NIL				
Disposed off during the quarter	NIL				
Remaining unresolved at the end of the quarter	NIL				

\* The above results were reviewed by the Audit Committee of the Board of Directors.

\* The above Audited Results were taken on record at the meeting of the Board of Directors held on 27th May, 2016.

\* The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures

\* During this quarter the Company has operated in 2 segments.

\* Exceptional item includes Impairment of Factory Buildings Rs. 68,98,141/- and Building demolition charges Rs. charges Rs. 23,19,525/-

Mumbai  
27-May-16

By order of the Board  
MSR Ayyangar  
Managing Director



## EMMESSAR BIOTECH &amp; NUTRITION LTD

Quarter and Year ended Segment wise Revenue Results and Capital Employed under Clause 41 of the Listing Agreement.					
[Rs. In Lakhs]					
	Current 3 months ended 31.03.2016	Preceding 3 months ended 31.12.2015	Corresponding Qtr ended 31.03.2015	Current year 31.03.2016	Previous year 31.03.2015
	Audited	Unaudited	Audited	Audited	Audited
1. Segment Revenue (Net Sales / Income)					
a. Healthcare	4.24	4.31	7.52	48.67	44.82
b. Fine Chemicals	47.00	11.50	0.02	148.77	174.20
c. Others	16.08	1.22	0.12	25.87	5.48
Total:	65.82	17.03	7.66	223.31	224.50
Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00
Net Sales / Income from Operations	65.82	17.03	7.66	223.31	224.50
2. Segment Results (Profit / Loss) before Tax and Interest					
a. Healthcare	1.72	2.20	4.11	31.23	26.30
b. Fine Chemicals	(6.60)	9.17	10.99	23.94	26.10
c. Others	16.08	1.22	0.12	25.87	5.48
Total:	11.20	12.59	15.22	81.04	57.88
Less:					
Interest	0.00	0.00	0.00	0.00	0.00
Other Unallocable Expenditure net off Unallocable Income	9.99	10.88	25.46	56.79	73.61
Total Profit / (loss) before Tax	1.21	1.71	(10.24)	24.25	(15.73)
3. Capital Employed (Segment Assets - Segment Liabilities)					
a. Healthcare	17.28	19.32	13.41	17.28	13.41
b. Fine Chemicals	34.78	42.29	28.38	34.78	28.38
c. Others	(16.94)	(57.23)	(37.51)	(16.94)	(37.51)
Total:	35.12	4.38	4.28	35.12	4.28

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on May 27, 2016

Mumbai  
27-May-16

By order of the Board  
MSR Ayyangar  
Managing Director



<b>EMMESSAR BIOTECH &amp; NUTRITION LTD</b>			
<b>Statements of Assets &amp; Liabilities</b>			
<b>(Rs. In Lakhs)</b>			
	<b>Particulars</b>	<b>As at 31.03.2016</b>	<b>As at 31.03.2015</b>
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>SHAREHOLDER'S FUNDS:</b>		
	(a) Share Capital	499.61	499.61
	(b) Reserves & Surplus	(408.70)	(362.17)
	<b>Sub-total Shareholder's funds</b>	<b>90.91</b>	<b>137.44</b>
<b>2</b>	<b>Non-current Liabilities</b>		
	(a) Deferred Tax Liabilities	-	10.04
	(b) Other Long-term Liabilities	61.42	28.12
	(c) Long Term Provisions	5.07	4.79
	<b>Sub-total Non-current liabilities</b>	<b>66.49</b>	<b>42.95</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Trade payables	20.07	30.90
	(b) Other current Liabilities	44.01	26.28
	(c) Short-term provisions	5.89	4.37
	<b>Sub-total Current Liabilities</b>	<b>69.97</b>	<b>61.55</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>227.37</b>	<b>241.94</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	(a) Fixed Assets	73.01	142.47
	(b) Deferred Tax Assets	11.35	-
	(c) Long-term loans and advances	17.48	11.90
	<b>Sub-total Non-current Assets</b>	<b>101.84</b>	<b>154.37</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Current Investments	0.60	0.57
	(b) Inventories	35.81	68.77
	(c) Trade Receivables	36.48	3.93
	(d) Cash & Cash equivalents	42.67	2.40
	(e) Short-term loans and advances	9.97	11.90
	<b>Sub-total Current Assets</b>	<b>125.53</b>	<b>87.57</b>
	<b>TOTAL ASSETS</b>	<b>227.37</b>	<b>241.94</b>

  
